With our firm mission "to develop drugs that patients await", Green Valley Research Institute, our R&D center, follows the innovative conception of "faithful, innovative, win-win and being persistent". Based on the transformation of new scientific paradigm which is called ‘holism’, we are committed to building a world-class innovative platform that integrates drug development and diagnosis innovations. The platform will be used to fight against brain diseases and other complex chronic diseases such as cancer, cardiovascular diseases and metabolic disorders by means of modern science technology, taking carbohydrate drugs as substance basis and pathological mechanism of brain diseases as main methods.
The Green Valley Research Institute is composed of Carbohydrate Chemistry Center, Carbohydrate Biology Center, Intestinal Micro-Ecological Center, Molecular Diagnosis Testing Center, Medical Artificial Intelligence Center and Clinical Research Center.
Famous Chinese oncological pharmacologist, and academician of Chinese Academy of Engineering. Dr. Ding Jian currently serves as the President of the College of Pharmacy, the University of Chinese Academy of Sciences, and Director of the Academic Committee of the Shanghai Institute of Materia Medica, the Chinese Academy of Sciences,and was previously the Head of the Shanghai Institute of Materia Medica, the Chinese Academy of Sciences.
His academic achievement focuses on mechanism research and development of medicines fighting against tumors and cancer. He led and established an anti-tumor drug screening and pharmacodynamic evaluation system that meets international standards, providing important technical support for China’s independent research and development of innovative anti-tumor drugs.
Professor and doctoral advisor, Secretary of the Party Committee, Deputy Director, researcher and principal investigator of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, chief scientist of the National 973 Program “Carbohydrate Chemistry and Carbohydrate Biology Research” Project, member of the “National Science Fund for Distinguished Young Scholars” and the "Hundred-Talent Program" of the Chinese Academy of Sciences.
In 2013, Dr. Geng Meiyu was listed in the Millions of Talent Project of the Chinese Academy of Sciences and was awarded as "Young and Middle-Aged Expert with Outstanding Contributions". In 2018, she won the 12th Guanghua Engineering Science and Technology Award.
Ph.D. in Biomathematics from UCLA School of Medicine, senior scientist and biomathematician at Banner Alzheimer’s Institute (BAI), Arizona, USA. Dr. Chen Kewei previously served as Director of the Neuroimaging Data Analysis Laboratory, and Director of Data Management and Statistics Department, ADCC, the National Alzheimer's Coordinating Center (NACC), USA, before joining Green Valley. He also served as a part-time professor at the School of Mathematics and Statistics, Arizona State University, USA, research professor at the Department of Neurology, College of Medicine-Phoenix, University of Arizona, and part-time professor at Beijing Normal University.
He has written and published hundreds of research articles. Based on statistics from the Google Scholar website, Professor Chen Kewei's h-index is 73. He specializes in research on Alzheimer's disease based on neuroimaging and focuses on disease prediction.
Ph.D. and doctoral advisor, Director of the Department of Computer Science, School of Information Engineering, Shanghai Maritime University. He concurrently serves as member of IEEE Shanghai Section, Director of Chinese Association for Artificial Intelligence, Vice Chairman of the Machine Learning Specialized Committee, Chinese Association for Artificial Intelligence, and Head of Shanghai Thought Science Research Society.
Professor Feng Jiali has been engaged in research on artificial intelligence for a long time, and proposed the "Attribute Theory" of human thinking for the first time in China.
PhD in Statistical Genetics and Bioinformatics. Prof. Feng Sheng once taught in University of Washington and Duke University successively. Since 2012, he has played senior management roles in Biogen and Abbvie, responsible for clinical research projects regarding big data and precision medicine. He specializes in bioinformatics-related applications in clinical study and how biological big data impact on clinical decision making.
Shanghai Institute of Materia Medica, China Academy of Sciences is our long-term strategic partner and we also established strategic partnership with Peking University, Rowan University and University of Washington in the US, University of Toronto in Canada, and other leading institutions of higher education and research institutes. We have developed in-depth cooperation in mechanism research, medicine development, disease diagnosis, non-drug treatment and related technology development.